A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma.

Trial Profile

A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Vorinostat (Primary) ; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 20 Apr 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2017.
    • 21 Apr 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top